Evolution of the Average Target: Quest Diagnostics Incorporated

Evolution of the Target Price: Quest Diagnostics Incorporated

Changes in Analyst Recommendations: Quest Diagnostics Incorporated

2a34f299122144168787eefac8fb.O7VTEIaiAv66W3rgSKHs5T0zekK5K2I4mDDzJ2dwh2c.eN0MeMLAZLT_DTOZfZC6unZAAhuUcS1p22-lbzQbwApchBcm0-xqjfxoHQ~faa8b575ae694925a6c32f7d22096e93
09-08 UBS Adjusts Quest Diagnostics Price Target to $245 From $232, Maintains Neutral Rating MT
07-30 Argus Research Adjusts Quest Diagnostics Price Target to $260 From $225, Maintains Buy Rating MT
07-28 JPMorgan Adjusts Price Target on Quest Diagnostics to $250 From $220, Maintains Neutral Rating MT
07-27 Rothschild & Co Redburn Adjusts Quest Diagnostics Price Target to $251 From $233, Maintains Buy Rating MT
07-24 UBS Adjusts Price Target on Quest Diagnostics to $232 From $220, Maintains Neutral Rating MT
07-24 Baird Adjusts Quest Diagnostics Price Target to $255 From $236, Maintains Neutral Rating MT
07-24 Barclays Raises Quest Diagnostics Price Target to $250 From $230, Maintains Overweight Rating MT
07-24 Mizuho Securities Adjusts Quest Diagnostics Price Target to $260 From $235, Maintains Outperform Rating MT
07-24 Deutsche Bank Adjusts Quest Diagnostics Price Target to $232 From $205, Maintains Hold Rating MT
07-24 Truist Raises Price Target on Quest Diagnostics to $250 From $225, Keeps Hold Rating MT
07-24 Morgan Stanley Adjusts PT on Quest Diagnostics to $260 From $226, Maintains Overweight Rating MT
07-23 Evercore ISI Cuts Quest Diagnostics Price Target to $240 From $225 MT
07-15 Leerink Partners Adjusts Quest Diagnostics Price Target to $244 From $240, Maintains Outperform Rating MT
05-18 Baird Adjusts Price Target on Quest Diagnostics to $232 From $229, Maintains Neutral Rating MT
04-27 Rothschild & Co Redburn Adjusts Price Target on Quest Diagnostics to $233 From $224, Maintains Buy Rating MT
04-22 UBS Adjusts Quest Diagnostics Price Target to $220 From $210, Maintains Neutral Rating MT
04-22 Truist Lifts Price Target on Quest Diagnostics to $225 From $220, Keeps Hold Rating MT
04-22 Evercore ISI Adjusts Price Target on Quest Diagnostics to $225 From $210, Maintains In Line Rating MT
04-22 Jefferies Adjusts Price Target on Quest Diagnostics to $225 From $220, Maintains Buy Rating MT
04-22 Barclays Adjusts Price Target on Quest Diagnostics to $230 From $225, Maintains Overweight Rating MT
04-22 Baird Adjusts Price Target on Quest Diagnostics to $229 From $224, Maintains Neutral Rating MT
04-21 Evercore ISI Adjusts Danaher Price Target to $225 From $210, Maintains Outperform Rating MT
04-21 Jefferies Raises Quest Diagnostics Price Target to $225 From $220 MT
04-21 Leerink Partners Adjusts Price Target on Quest Diagnostics to $240 From $235, Maintains Outperform Rating MT
04-14 Baird Adjusts Price Target on Quest Diagnostics to $224 From $219, Maintains Neutral Rating MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
-0.29%
+28.81%
+5.51%
+20.54%
+17.46%
+9.04%
+30.95%
+20.08%
+9.75%
+7.3%
Average +14.91%
Weighted average by Cap. +16.54%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
247.45USD
Average target price
246.73USD
Spread / Average Target
-0.29%
High Price Target
265.00USD
Spread / Highest target
+7.09%
Low Price Target
204.00USD
Spread / Lowest Target
-17.56%

Analyst Consensus Detail

Consensus revision (last 18 months)

Trader
Investor
Global
Quality
ESG MSCI
AA
  1. Stock Market
  2. Stocks
  3. DGX Stock
  4. Consensus Quest Diagnostics Incorporated
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!